(Q46569270)

23 December 2017

title

Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure (English)

1 reference

23 December 2017

0 references

3

Ramzi Ajjan

0 references

author name string

Lip Bun Tan

series ordinal

1

1 reference

23 December 2017

Nigel Lewis

series ordinal

2

1 reference

23 December 2017

Ramzi Ajjan

series ordinal

3

1 reference

23 December 2017

publication date

1 June 2008

1 reference

23 December 2017

Expert Review of Cardiovascular Therapy

published in

1 reference

23 December 2017

volume

6

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

623-627

1 reference

23 December 2017

Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

The PROactive study: some answers, many questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Role of cardiac power in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Measuring cardiac power output -- the acid test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

The DREAM trial – Authors' reply

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.5.623

21 January 2018

Identifiers

DOI

10.1586/14779072.6.5.623

1 reference

23 December 2017

1 reference

23 December 2017